Adverse effects of daily oral pre-exposure prophylaxis in men who have sex with men and transgender women: a systematic review and meta-analysis Authors: Marcos Pereira, Caroline Tianeze de Castro, Laio Magno, Tarcio de Almeida Oliveira, Fabiane Soares Gomes, Fabiane Maria Fernandes Neves, Pedro Rafael dos Santos do Nascimento, Ines Dourado Published: 2023 ABSTRACT Abstract:The adverse effects of oral pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate are barriers to PrEP initiation and continuation. Although serious effects are rare and predictable, evidence for this assessment among men who have sex with men (MSM) and transgender women (TGW) is still limited. This study assesses the adverse effects of daily oral PrEP in MSM and TGW. This is a systematic review and meta-analysis of clinical trials and cohort studies on the use of daily oral PrEP selected from the PubMed/MEDLINE, Embase, LILACS, and Cochrane CENTRAL databases. Data extraction included adverse effects and changes in renal and hepatic markers. Random effects models were used to summarize the risk of adverse effects throughout the study. Heterogeneity was assessed using the Cochran’s Q test and the inconsistency test (I2). The risk of bias and the certainty of the evidence were assessed using the Cochrane Collaboration recommendations. The search identified 653 references. Of these, 10 were selected. All studies assessed the eligibility of renal and hepatic markers. The use of daily oral PrEP was not associated with grade 3 or 4 adverse events (RR = 0.99; 95%CI: 0.83-1.18; I2 = 26.1%), any serious adverse event (RR = 1.04; 95%CI: 0.58-1.87; I2 = 88.4%), grade 3+4 creatinine level (RR = 0.66; 95%CI: 0.24-1.84; I2 = 79.9%), and grade 3 or 4 hypophosphatemia (RR = 0.56; 95%CI: 0.15-2.10). The certainty of the evidence ranged from high to moderate for the outcomes analyzed. Daily oral PrEP is safe and well tolerated by MSM and TGW. Adverse effects were minimal and evenly distributed between intervention and control. Introduction Pre-exposure prophylaxis (PrEP) is one of the key combination prevention strategies to control the HIV epidemic, especially for populations at substantial risk of HIV infection 1 , as recommended by the World Health Organization (WHO) in September 2015. Oral PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is highly effective in preventing HIV infection when used as recommended by WHO guidelines 2 . The use of PrEP requires an initial clinical assessment by anamnesis, an evaluation of contraindications, and monitoring of adverse events. Although oral PrEP is well tolerated, it can lead to mild or moderate adverse events and rarely to severe conditions 3 . Therefore, due to the risk of nephrotoxicity, the WHO recommends that participants undergo medical examinations before starting PrEP, to identify any history of kidney injury and thus exclude the association with the medication after initiation 4 . Moreover, creatinine levels should be measured during PrEP initiation and every six months, with more frequent monitoring in individuals with kidney-related comorbidities and less frequent monitoring in individuals aged < 45 years 4 . Evidence from clinical trials and cohort studies on the use of PrEP shows rare adverse effects and changes in renal 3 , 5 , 6 and bone markers 7 . These changes are generally mild and do not lead to significant effects 8 . However, these studies analyzed multiple groups, but not specifically men who have sex with men (MSM) or transgender women (TGW). A study with a representative sample of transgender individuals in the United States recorded higher rates of certain adverse effects associated with PrEP, such as nausea, diarrhea, kidney failure, and changes in bone density, compared with studies that included only MSM in the same country, despite the limitations and differences in the assessment of these outcomes between the studies 9 , 10 . A systematic review found that the risk of a decline in estimated creatinine clearance may differ slightly according to gender 5 , but cisgender and transgender or non-binary individuals showed no difference regarding risk, although data were scarce. Therefore, it is essential to understand that these findings are not universally applicable to all individuals in each group. Therefore, investigating the adverse effects of PrEP may increase the knowledge about these effects in PrEP users. Moreover, as adverse events can affect the effectiveness of medications 11 , estimating the adverse effects associated with PrEP in MSM and TGW is important, since they are at a high risk of HIV infection. Low adherence to PrEP among individuals for whom it is indicated is a substantial problem affecting many groups. The short- and long-term safety of PrEP among individuals at risk of HIV infection raises doubts. Qualitative studies with MSM and TGW reported that concerns about side effects were associated with a lower willingness to take PrEP 9 , 12 , 13 , 14 , as well as a lack of research with TGW 12 . Moreover, individuals from different social groups, such as MSM and TGW, may have different risks of adverse reactions to medications, which may be related to failures in treatment follow-up due to factors that alter the risk of problem occurrence or monitoring 9 , 12 , 14 , 15 . Notably, these groups are a priority for HIV prevention, especially transgender individuals considering using PrEP to prevent HIV, who are concerned about the adverse effects and the interactions of the medication with gender-affirming hormone therapy 9 , 15 . Therefore, assessing the adverse effects of using oral PrEP in different key populations, such as MSM and TGW, can provide a better understanding of adverse effects in these populations, since systematic reviews have not yet stratified the adverse effects of subgroups 3 , 6 , focusing, when available, on renal parameters 5 . On the other hand, fear of the adverse effects of PrEP is considered a barrier for individuals start using PrEP 16 , 17 . Understanding the barriers to PrEP use and producing new evidence on the topic, such as the side effects of PrEP, is essential to ensure its effective implementation 18 , particularly among populations with disproportionate and/or increasing rates of HIV infection. Moreover, the use of oral PrEP has increased, along with the evaluation of recommendations for monitoring its adverse effects. Therefore, this study aimed to assess the adverse effects of daily oral PrEP in MSM and TGW. Methods Protocol and registration This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 19 and was based on the methodological recommendations of the Cochrane Collaboration 20 . The study protocol was registered in the PROSPERO database (protocol n. CRD42020203079). The study answers the research question: “What are the adverse effects of oral PrEP in MSM and TGW compared with individuals who do not use this prophylaxis?”. Eligibility criteria The PICOT structure was used to define the following eligibility criteria: The populations of interest (P) were MSM and TGW at any age, regardless of sexual orientation; The intervention (I) considered was the daily use of oral PrEP: (i) emtricitabine 200mg + tenofovir disoproxil fumarate 300mg (FTC/TDF); (ii) emtricitabine 200mg + tenofovir alafenamide (TAF) 25mg (FTC/TAF); or (iii) tenofovir disoproxil fumarate (TDF); The comparison group (C) consisted of individuals who did not use PrEP (control group). A comparison group was included to avoid or control for possible nocebo effects in adverse events between the groups; The outcomes of interest (O) were any serious adverse event, any grade 3 or 4 event, total grade creatinine, and grade 3 or 4 hypophosphatemia (Material Suplementar 1: https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-1-e00089522_4764.pdf) The study design (T) included cohort studies and clinical trials on PrEP. This study did not apply restrictions on age, origin, or language of publication. Studies on women, mixed groups (e.g., female sex workers and MSM), serodiscordant heterosexual couples, and sex workers were excluded. Search strategy Searches were performed in the bibliographic databases PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, LILACS, and OpenGray in May 2020 and updated in April 2022. Medical Subject Headings (MeSH), Emtree, and Health Sciences (DeCS) keywords were used to identify studies published in these databases: “Pre-Exposure Prophylaxis”, “chemoprevention”, “HIV”, “human immunodeficiency virus infection”, “Drug-Related Side Effects and Adverse Reactions”, and “Adverse Drug Reaction”. These keywords were combined with the Boolean operators “OR” and “AND” and their entry terms in all databases. This study also searched grey literature in ProQuest and references to systematic reviews on PrEP to identify studies not included in the electronic search. Material Suplementar 2(https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-2-e00089522_8074.pdf) shows the details of the search process. Study selection The publications found in the databases were inserted into the Rayyan application (https://www.rayyan.ai/), a free software that helps select studies. Two evaluators (M.P. and T.A.O.) independently screened titles and abstracts to identify potentially eligible studies. The eligibility of the publications that met the inclusion criteria in the initial phase was confirmed by reading them in full. Studies that met all eligibility criteria were included in the qualitative synthesis. Disagreements regarding the inclusion of studies were resolved by a third evaluator (L.M.). Data extraction Using a standardized form, the reviewers (M.P., C.T.C., T.A.O., F.S.G., P.R.S.N., and F.M.F.N.) independently extracted data from the included studies. Extracted data included year of publication, study design, study site, sample size, mean age of participants, medications used, adverse reactions identified, and the criteria and frequency of measurement of adverse effects. At the end of this study, the lead author (M.P.) reviewed all the information. Moreover, authors whose studies were not available in the databases were contacted by the corresponding author to request the full text. Methodological quality assessment The methodological quality of all the studies that met the eligibility criteria was assessed using the risk of bias scale for estimates of effectiveness and safety in non-randomized intervention studies recommended by the Cochrane Collaboration, the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) 21 . This tool assesses seven domains of bias classified by moment of occurrence: pre-intervention (bias due to confounding and bias in selection of participants into the study), at intervention (bias in classification of interventions), and post-intervention (bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes, and bias in selection of the reported result). The items were classified as low, moderate, severe, or critical risk of bias or no information, according to the descriptions in the Cochrane Handbook for Systematic Reviews of Interventions 20 . Statistical analysis A random effects meta-analysis was conducted using the rate of adverse events for the following outcomes: any serious adverse event, any grade 3 or 4 event, total grade creatinine (subgroups 1+2 and 3+4), and grade 3 or 4 hypophosphatemia (Material Suplementar 1: https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-1-e00089522_4764.pdf). These are described as follows: Any serious adverse event: any unforeseen medical event that, at any dose, leads to death, is life-threatening, requires hospitalization or prolongation of an existing hospitalization, or causes persistent or significant disability or incapacity 22 ; Any grade 3 or 4 event: severe or potentially life-threatening event; Total grade creatinine (subgroups 1+2 and 3+4): all serum creatinine elevations from 1.1 to 1.3 times the upper limit of typical levels. Grade 2 and higher events include serum creatinine elevations of 1.3 to 1.8 times the upper limit of typical levels or 1.3 to 1.5 times the participants’ baseline value 22 ; Hypophosphatemia: grade 3 includes serum phosphate < 2.0-1.0mg/dL or < 0.6-0.3mmol/L. Grade 4 includes serum phosphate < 1.0mg/dL or < 0.3mmol/L and life-threatening consequences 22 . These biochemical outcomes were selected because when they are altered in individuals under PrEP, discontinuation is recommended. In studies with no events in the intervention or control groups, a value of one was entered to estimate the summary mean. The measures adopted to summarize the results were the relative risk (RR) and their respective 95% confidence intervals (95%CI). Cochran’s Q statistical test and the inconsistency test (I2) were used to assess the heterogeneity and consistency of the studies 23 . In the presence of heterogeneity (p < 0.05; I2 > 25%), a random model with inverse variance was used, weighted by the results of the individual studies 24 . A minimum of eight studies were considered to assess publication bias by preparing the funnel plot and performing Egger’s test 20 , 25 . Assessment of the certainty of the evidence The certainty of the evidence was assessed using GRADEpro software (https://www.gradepro.org/). The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system classifies the quality of the evidence into four levels: high, moderate, low, and very low, according to study design limitations, indirect evidence, inconsistency of results, imprecision of results, and a significant probability of publication bias 26 . Results Study selection We identified 653 references using the search strategies adopted, of which 99 were selected to assess their eligibility and 10 studies, that is, 16 articles 10 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 were included in the systematic review (Figure 1). The exclusion criteria involved the study population (n = 20), the outcomes analyzed (n = 23), the PrEP regimen (n = 17), the clinical trial protocol (n = 15), and the cross-sectional study design (n = 1) (Figure 1). Figure 1Flowchart of study selection.PrEP: pre-exposure prophylaxis. Note: the reasons for excluding publications can be accessed in the Supplementary Material 3 (https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-3-e00089522_3123.pdf). Flowchart of study selection. Assessment of risk of bias Figure 2 shows the results of the quality assessment of the included studies. Among them, risk of bias was predominantly low 10 , 29 , 30 , 36 , 39 , 40 and moderate 32 , 33 , 34 , 38 , 41 , and two were critical 28 , 37 . The main criteria contributing to moderate or critical risk of bias were bias due to confounding, bias due to missing data, and bias in in measurement of outcomes. Figure 2Assessment of risk of bias in non-randomized studies (ROBINS-I - Risk of Bias in Non-randomized Studies of Interventions).Domains: D1 - bias due to confounding; D2 - bias in selection of participants into the study; D3 - bias in classification of interventions; D4 - bias due to deviations from intended interventions; D5 - bias due to missing data; D6 - bias in measurement of outcomes; D7 - bias in selection of the reported result. Assessment of risk of bias in non-randomized studies (ROBINS-I - Risk of Bias in Non-randomized Studies of Interventions). Characterization and qualitative synthesis of the selected studies Table 1 presents the main characteristics of the included studies. We analyzed information on adverse effects (US CDC PrEP 31 , 34 , iPrEx 10 , 27 , 30 , US PrEP Demonstration Project 39 , 40 , and PrEPare 36 , 37 ) and study extension (PrePare ATN 08 3MV 38 , ATN 117 35 , ADAPT Study 29 , HPTN 073 33 , DISCOVER 32 , 41 , and PROUD 28 . Table 1Characteristics of selected studies on adverse effects of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW).Authors (Year)StudyStudy designMedicationPopulationAge (years)CountriesFollow-upParticipantsHormone use in the PrEP groupLiu et al. 31 (2011)US CDC PrEPPhase II randomized, double-blind, placebo-controlled extended safety trialDaily oral TDF 300mgMSM18-60United States24 months (immediate arm) or 15 months (delayed arm)184Testosterone and growth hormone (17%)Grohskopf et al. 34 (2013)US CDC PrEPRandomized, double-blind, placebo-controlled trialDaily oral TDF 300mgMSM18-60United States24 months400Not reportedGrant et al. 10 (2010)IprExPhase III randomized, double-blind, placebo-controlled studyTDF/Daily FTCMSM/TGW18-67Brazil, Ecuador, Peru, South Africa, Thailand, and the United States1.2-2.8 years2,499Not reportedSolomon et al. 30 (2014)IprExPhase III randomized, double-blind, placebo-controlled studyTDF/Daily FTCMSM/TGW18-67Brazil, Ecuador, Peru, South Africa, Thailand, and the United States1.2-2.8 years2,499Not reportedDeutsch et al. 27 (2015)IprExPhase III randomized, double-blind, placebo-controlled studyTDF/Daily FTCMSM/TGW18-67Brazil, Ecuador, Peru, South Africa, Thailand, and the United States2 years2,499Exogenous female hormone (20%)Liu et al. 39 (2016)US PrEP Demonstration ProjectProspective cohort studyTDF/Daily FTCMSM/TGW18-65United States48 weeks557Testosterone or anabolic steroid (1.5%)Tang et al. 40 (2018)US PrEP Demonstration ProjectProspective cohort studyTDF/Daily FTCMSM/TGW18-65United States48 weeks557Not reportedMcCormack et al. 28 (2016)PROUDOpen-label randomized trialTDF/Daily FTCMSM29-43United Kingdom48 weeks544Not reportedHosek et al. 38 (2013)PrEPare ATN 08 3MVPilot study using a randomized 3-arm designTDF/Daily FTCYoung MSM18-22United States24 weeks68Not reportedHosek et al. 36 (2017)PrEPareProspective cohort study/PrEP Demonstration ProjectTDF/Daily FTCYoung MSM15-17United States48 weeks78Not reportedHosek et al. 37 (2017)PrEPareProspective cohort study/PrEP Demonstration ProjectTDF/Daily FTCYoung MSM18-22United States48 weeks200Not reportedHavens et al. 35 (2017)ATN 117Prospective cohortstudy/PrEP Demonstration ProjectTDF/Daily FTCYoung MSM15-22United States48 weeks101Not reportedWheeler et al. 33 (2019)HPTN 073Non-randomized open-label PrEPTDF/Daily FTCMSM26 (IQR: 23-32)United States52 weeks161Anabolic steroids and female sex hormonesGrant et al. 29 (2018)067/ADAPT StudyPhase II randomized, open-labelFTC/Daily vs. non-daily oral TDFMSM/TGW≥ 18Thailand34 weeks357 Mayer et al. 32 (2020)DISCOVERPhase III randomized, double-blind, multicenter, active-controlled trialDaily tablets of FTC (200mg) and TAF (25mg) MSM/TGW34 (IQR: 28-44) 96 weeks5,387Gender-affirming hormone therapy (17 TGW)Ogbuagu et al. 41 (2021)DISCOVERPhase III randomized, double-blind, multicenter, active-controlled trialDaily tablets of FTC (200mg) and TAF (25mg) MSM/TGW34 (IQR: 28-44) 96 weeks5,387Not reportedFTC: emtricitabine; IQR: interquartile range; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate. Table 1Characteristics of selected studies on adverse effects of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW).Authors (Year)StudyStudy designMedicationPopulationAge (years)CountriesFollow-upParticipantsHormone use in the PrEP groupLiu et al. 31 (2011)US CDC PrEPPhase II randomized, double-blind, placebo-controlled extended safety trialDaily oral TDF 300mgMSM18-60United States24 months (immediate arm) or 15 months (delayed arm)184Testosterone and growth hormone (17%)Grohskopf et al. 34 (2013)US CDC PrEPRandomized, double-blind, placebo-controlled trialDaily oral TDF 300mgMSM18-60United States24 months400Not reportedGrant et al. 10 (2010)IprExPhase III randomized, double-blind, placebo-controlled studyTDF/Daily FTCMSM/TGW18-67Brazil, Ecuador, Peru, South Africa, Thailand, and the United States1.2-2.8 years2,499Not reportedSolomon et al. 30 (2014)IprExPhase III randomized, double-blind, placebo-controlled studyTDF/Daily FTCMSM/TGW18-67Brazil, Ecuador, Peru, South Africa, Thailand, and the United States1.2-2.8 years2,499Not reportedDeutsch et al. 27 (2015)IprExPhase III randomized, double-blind, placebo-controlled studyTDF/Daily FTCMSM/TGW18-67Brazil, Ecuador, Peru, South Africa, Thailand, and the United States2 years2,499Exogenous female hormone (20%)Liu et al. 39 (2016)US PrEP Demonstration ProjectProspective cohort studyTDF/Daily FTCMSM/TGW18-65United States48 weeks557Testosterone or anabolic steroid (1.5%)Tang et al. 40 (2018)US PrEP Demonstration ProjectProspective cohort studyTDF/Daily FTCMSM/TGW18-65United States48 weeks557Not reportedMcCormack et al. 28 (2016)PROUDOpen-label randomized trialTDF/Daily FTCMSM29-43United Kingdom48 weeks544Not reportedHosek et al. 38 (2013)PrEPare ATN 08 3MVPilot study using a randomized 3-arm designTDF/Daily FTCYoung MSM18-22United States24 weeks68Not reportedHosek et al. 36 (2017)PrEPareProspective cohort study/PrEP Demonstration ProjectTDF/Daily FTCYoung MSM15-17United States48 weeks78Not reportedHosek et al. 37 (2017)PrEPareProspective cohort study/PrEP Demonstration ProjectTDF/Daily FTCYoung MSM18-22United States48 weeks200Not reportedHavens et al. 35 (2017)ATN 117Prospective cohortstudy/PrEP Demonstration ProjectTDF/Daily FTCYoung MSM15-22United States48 weeks101Not reportedWheeler et al. 33 (2019)HPTN 073Non-randomized open-label PrEPTDF/Daily FTCMSM26 (IQR: 23-32)United States52 weeks161Anabolic steroids and female sex hormonesGrant et al. 29 (2018)067/ADAPT StudyPhase II randomized, open-labelFTC/Daily vs. non-daily oral TDFMSM/TGW≥ 18Thailand34 weeks357 Mayer et al. 32 (2020)DISCOVERPhase III randomized, double-blind, multicenter, active-controlled trialDaily tablets of FTC (200mg) and TAF (25mg) MSM/TGW34 (IQR: 28-44) 96 weeks5,387Gender-affirming hormone therapy (17 TGW)Ogbuagu et al. 41 (2021)DISCOVERPhase III randomized, double-blind, multicenter, active-controlled trialDaily tablets of FTC (200mg) and TAF (25mg) MSM/TGW34 (IQR: 28-44) 96 weeks5,387Not reportedFTC: emtricitabine; IQR: interquartile range; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate. Characteristics of selected studies on adverse effects of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW). FTC: emtricitabine; IQR: interquartile range; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate. The studies consisted of clinical trials (n = 7) and cohort studies (n = 3) and mostly involved MSM (n = 4), young MSM (n = 4), and MSM/TGW (n = 2). Moreover, the years of publication ranged from 2011 to 2021, the samples from 78 to 5,387 participants, and the ages from 15 to 67 years. Four studies had a follow-up duration of ≤ 1 year 28 , 29 , 38 , 40 and the others < 1 year. Table 2 presents the adverse event monitoring data evaluated at baseline and in the study segment. All studies addressed renal function markers at eligibility or baseline. Hepatic markers were reported in only five studies (US CDC PrEP, iPrEx, PrEPare, and ADAPT Study). Markers of adverse effects were assessed at different times in the participants’ segment and, in most cases, classified according to the U.S. Division of AIDS criteria 22 . Table 2Monitoring of the adverse effects of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW).Authors (Year)StudyStudy periodRenal functionHepatic functionBiochemical parameters in eligibilityMonitoring of adverse eventsOutcome measuresLiu et al. 31 (2011)US CDC PrEPFebruary 2005 to July 2007/January 2005 to July 2007YesYesCockroft-Gault creatinine clearance; spot urine calcium/creatinine ratioEach quarterly visitNoneGrohskopf et al. 34 (2013)US CDC PrEPFebruary 2005 to July 2007/January 2005 to July 2007YesYesCockcroft-Gault creatinine clearance; serum creatinine; phosphorusWeeks 1, 3, 6, 9, 12, 15, 18, 21, and 24DAIDS toxicity tables (January 2004)Grant et al. 10 (2010)iPrExJuly 2007 to December 2009YesYesSerum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucoseWeeks 4, 8, 12, 16, and 24 and then every 12 weeksGrade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004)Solomon et al. 30 (2014)iPrExJuly 2007 to December 2009YesYesSerum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucoseWeeks 4, 8, 12, 16, and 24 and then every 12 weeksGrade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004)Deutsch et al. 27 (2015)iPrExJuly 2007 to December 2009YesYesSerum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucoseWeeks 4, 8, 12, 16, and 24 and then every 12 weeksGrade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004)Liu et al. 39 (2016)US PrEP Demonstration ProjectOctober 1, 2012, to January 23,2014Yes Cockcroft-Gault creatinine clearance and eGFR (CKD-EPI); urine protein dipstick testWeeks 4, 12, 24, 36, and 48DAIDS adverse event grading table version 1.0, December 2004, and the DAIDS Male Genital Grading TableTang et al. 40 (2018)US PrEP Demonstration ProjectOctober 1, 2012, to January 23,2014Yes Cockcroft-Gault creatinine clearance and eGFR (CKD-EPI) Urine protein dipstick testWeeks 4, 12, 24, 36, and 48DAIDS adverse event grading table version 1.0, December 2004, and the DAIDS Male Genital Grading TableMcCormack et al. 28 (2016)PROUDNovember 2012 to October 2016Yes Serum creatinine; urine protein dipstick testAnnualy and every 3 monthsNoneHosek et al. 38 (2013)PrEPare ATN 08 3MVAugust 2005 to November 2006YesYesHepatic and pancreatic function tests; urine dipstick testing for protein and glucoseEvery 4 weeks for 24 weeksExpedited Adverse Event Reporting (grade 2 and higher)Hosek et al. 36 (2017)PrEPareJanuary to September 2013YesYesRenal function: phosphate, blood urea nitrogen, creatinine, and urine dipstick testing for protein and glucose; pancreatic function: amylase; hepatic function: AST, ALT, alcaline phosphatase, total bilirubin, and direct bilirubinMonthly in the first quarter (weeks 4, 8, and 12) and then quarterly until 48 weeksATN adverse event severity grading table for adolescents (October 2006 to March 2011)/Manual for Expedited Reporting of Adverse Events to DAIDS (version 2.0, March 2011)Hosek et al. 37 (2017)PrEPareAugust 2013 to September 2014YesYesRenal function: phosphate, blood urea nitrogen, creatinine, and urine dipstick testing for protein and glucose; pancreatic function: amylase; hepatic function: AST, ALT, alcaline phosphatase, total bilirubin, and direct bilirubinMonthly in the first quarter (weeks 4, 8, and 12) and then quarterly until 48 weeksATN adverse event severity grading table for adolescents (October 2006 to March 2011)/Manual for Expedited Reporting of Adverse Events to DAIDS (version 2.0, March 2011)Havens et al. 35 (2017)ATN 117December 2012 to October 2014YesYesSerum creatinine, albumin, calcium, phosphate, glucose, protein, and retinol binding proteinWeeks 4, 8, 12, 24, 36, and 48NoneGrant et al. 29 (2018)067/ADAPT StudyJuly 4, 2012, to May 6, 2014YesYesRenal function: estimated creatinine clearance, phosphate; hepatic function: AST and ALTWeeks 4, 10, 18, and 30NoneWheeler et al. 33 (2019)HPTN 073February 2013 to September 2014Yes Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucoseAt screening, 4 and 13 weeks after inclusion, and then quarterly; at screening and quarterly after inclusionNoneMayer et al. 32 (2020)DISCOVERSeptember 13, 2016, to June 30, 2017Yers Cockcroft-Gault creatinine clearance; urinary RBP; lipids and fasting glucose; urine protein and urine protein to creatinine ratioWeeks 4 and 12 and then every 12 weeksNoneOgbuagu et al. 41 (2021)DISCOVERSeptember 13, 2016, to June 30, 2017Yes Cockcroft-Gault creatinine clearance ; urinary RBP; lipids and fasting glucose; urine protein and urine protein to creatinine ratioWeeks 4 and 12 and then every 12 weeksNoneALT: alanine aminotransferase; AST: aspartate aminotransferase; ATN: Adolescent Trials Network; DAIDS: U.S. Division of AIDS; eGFR: estimated glomerular filtration rate; RBP: retinol binding protein. Table 2Monitoring of the adverse effects of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW).Authors (Year)StudyStudy periodRenal functionHepatic functionBiochemical parameters in eligibilityMonitoring of adverse eventsOutcome measuresLiu et al. 31 (2011)US CDC PrEPFebruary 2005 to July 2007/January 2005 to July 2007YesYesCockroft-Gault creatinine clearance; spot urine calcium/creatinine ratioEach quarterly visitNoneGrohskopf et al. 34 (2013)US CDC PrEPFebruary 2005 to July 2007/January 2005 to July 2007YesYesCockcroft-Gault creatinine clearance; serum creatinine; phosphorusWeeks 1, 3, 6, 9, 12, 15, 18, 21, and 24DAIDS toxicity tables (January 2004)Grant et al. 10 (2010)iPrExJuly 2007 to December 2009YesYesSerum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucoseWeeks 4, 8, 12, 16, and 24 and then every 12 weeksGrade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004)Solomon et al. 30 (2014)iPrExJuly 2007 to December 2009YesYesSerum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucoseWeeks 4, 8, 12, 16, and 24 and then every 12 weeksGrade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004)Deutsch et al. 27 (2015)iPrExJuly 2007 to December 2009YesYesSerum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucoseWeeks 4, 8, 12, 16, and 24 and then every 12 weeksGrade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004)Liu et al. 39 (2016)US PrEP Demonstration ProjectOctober 1, 2012, to January 23,2014Yes Cockcroft-Gault creatinine clearance and eGFR (CKD-EPI); urine protein dipstick testWeeks 4, 12, 24, 36, and 48DAIDS adverse event grading table version 1.0, December 2004, and the DAIDS Male Genital Grading TableTang et al. 40 (2018)US PrEP Demonstration ProjectOctober 1, 2012, to January 23,2014Yes Cockcroft-Gault creatinine clearance and eGFR (CKD-EPI) Urine protein dipstick testWeeks 4, 12, 24, 36, and 48DAIDS adverse event grading table version 1.0, December 2004, and the DAIDS Male Genital Grading TableMcCormack et al. 28 (2016)PROUDNovember 2012 to October 2016Yes Serum creatinine; urine protein dipstick testAnnualy and every 3 monthsNoneHosek et al. 38 (2013)PrEPare ATN 08 3MVAugust 2005 to November 2006YesYesHepatic and pancreatic function tests; urine dipstick testing for protein and glucoseEvery 4 weeks for 24 weeksExpedited Adverse Event Reporting (grade 2 and higher)Hosek et al. 36 (2017)PrEPareJanuary to September 2013YesYesRenal function: phosphate, blood urea nitrogen, creatinine, and urine dipstick testing for protein and glucose; pancreatic function: amylase; hepatic function: AST, ALT, alcaline phosphatase, total bilirubin, and direct bilirubinMonthly in the first quarter (weeks 4, 8, and 12) and then quarterly until 48 weeksATN adverse event severity grading table for adolescents (October 2006 to March 2011)/Manual for Expedited Reporting of Adverse Events to DAIDS (version 2.0, March 2011)Hosek et al. 37 (2017)PrEPareAugust 2013 to September 2014YesYesRenal function: phosphate, blood urea nitrogen, creatinine, and urine dipstick testing for protein and glucose; pancreatic function: amylase; hepatic function: AST, ALT, alcaline phosphatase, total bilirubin, and direct bilirubinMonthly in the first quarter (weeks 4, 8, and 12) and then quarterly until 48 weeksATN adverse event severity grading table for adolescents (October 2006 to March 2011)/Manual for Expedited Reporting of Adverse Events to DAIDS (version 2.0, March 2011)Havens et al. 35 (2017)ATN 117December 2012 to October 2014YesYesSerum creatinine, albumin, calcium, phosphate, glucose, protein, and retinol binding proteinWeeks 4, 8, 12, 24, 36, and 48NoneGrant et al. 29 (2018)067/ADAPT StudyJuly 4, 2012, to May 6, 2014YesYesRenal function: estimated creatinine clearance, phosphate; hepatic function: AST and ALTWeeks 4, 10, 18, and 30NoneWheeler et al. 33 (2019)HPTN 073February 2013 to September 2014Yes Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucoseAt screening, 4 and 13 weeks after inclusion, and then quarterly; at screening and quarterly after inclusionNoneMayer et al. 32 (2020)DISCOVERSeptember 13, 2016, to June 30, 2017Yers Cockcroft-Gault creatinine clearance; urinary RBP; lipids and fasting glucose; urine protein and urine protein to creatinine ratioWeeks 4 and 12 and then every 12 weeksNoneOgbuagu et al. 41 (2021)DISCOVERSeptember 13, 2016, to June 30, 2017Yes Cockcroft-Gault creatinine clearance ; urinary RBP; lipids and fasting glucose; urine protein and urine protein to creatinine ratioWeeks 4 and 12 and then every 12 weeksNoneALT: alanine aminotransferase; AST: aspartate aminotransferase; ATN: Adolescent Trials Network; DAIDS: U.S. Division of AIDS; eGFR: estimated glomerular filtration rate; RBP: retinol binding protein. Monitoring of the adverse effects of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW). ALT: alanine aminotransferase; AST: aspartate aminotransferase; ATN: Adolescent Trials Network; DAIDS: U.S. Division of AIDS; eGFR: estimated glomerular filtration rate; RBP: retinol binding protein. Meta-analysis results Figure 3 shows the results of the meta-analysis. Publication bias could not be assessed due to the small number of studies analyzed. We obtained the following results: Figure 3Forest plots for adverse effects of the use of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW).95%CI: 95% confidence interval; RR: relative risk. * The weights are from the random effects model; ** The weights are from the random effects model; continuity correction applied to studies with zero cells; *** The weights and the test for heterogeneity between subgroups are from the random effects model. Forest plots for adverse effects of the use of daily oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) and transgender women (TGW). Any grade 3 or 4 event: no statistically significant effect (RR = 0.99; 95%CI: 0.83-1.18; I2 = 26.1%) on the total number of grade 3 or 4 adverse events in PrEP users compared with the control group (Figure 3a); Any serious adverse event: six studies reported serious adverse effects. The use of oral PrEP was not associated with serious adverse effects (RR = 0.99; 95%CI: 0.54-1.80; I2 = 90.1%) (Figure 3b); Creatinine changes: four studies reported data on serious adverse events related to creatinine, but only two were included in the meta-analysis due to the number of observations (> 0). The use of daily oral PrEP was not associated with the occurrence of grade 1 or 2 (RR = 1.12; 95%CI: 0.34-3.65; I2 = 0%) or grade 3 or 4 creatinine levels (RR = 0.66; 95%CI: 0.24-1.84; I2 = 79.9%) (Figure 3c); Grade 3 or 4 hypophosphatemia: the meta-analyses of grade 3 or 4 hypophosphatemia found no significant difference (p = 0.53) between the number of events in PrEP users compared with the control group (RR = 0.56; 95%CI: 0.15-2.10). Heterogeneity between trials was moderate (I2 = 48.3%) (Figure 3d). Certainty of evidence The certainty of the evidence for any grade 3 or 4 event and creatinine changes was high. However, it was moderate for the outcomes of any serious adverse event and grade 3 or 4 hypophosphatemia due to the high unexplained heterogeneity, the few included studies in the meta-analysis, and the number of outcome observations (Table 3). Table 3Certainty of the evidence of the outcomes included in the meta-analysis. Adverse effects of oral daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) in men who have sex with men (MSM) and transgender women (TGW).OutcomeParticipants (studies)Relative effect [RR (95%CI)]Anticipated absolute effects [% (95%CI)] Certainty *OutcomeWithout PrEPWith PrEPDifference Any grade 3 or 4 event7,541 (4 RCTs)0.99 (0.83-1.18)10.610.4 (8.8-12.5)0.1% lower (1.8 lower to 1.9 higher)⨁⨁⨁⨁ HighDaily oral PrEP use was not associated with any grade 3 or 4 eventAny serious adverse event8,683 (7 RCTs)1.04 (0.58-1.87)5.96.2 (3.4-11.1)0.2% higher (2.5 lower to 5.2 higher)⨁⨁⨁◯ Moderate **Daily oral PrEP use was not associated with any serious adverse eventChanges in creatinine4,946 (6 RCTs)0.79 (0.40-1.56)1.91.5 (0.8-3.0)0.4% lower (1.2 lower to 1.1 higher)⨁⨁⨁⨁ HighDaily oral PrEP use was not associated with renal dysfunctionGrade 3 or 4 hypophosphatemia3,145 (3 RCTs)0.56 (0.15-2.10)1.20.7 (0.2-2.5)0.5% lower (1.0 lower to 1.3 higher)⨁⨁⨁◯ Moderate ***Daily oral PrEP use was not associated with renal dysfunction95%CI: 95% confidence interval; RCT: randomized clinical trial; RR: risk ratio.Note: the risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI).* GRADE levels of evidence: High certainty (the authors have a lot of confidence that the true effect is similar to the estimated effect), Moderate certainty (the authors believe that the true effect is probably close to the estimated effect, but could also be markedly different), Low certainty (the true effect might be markedly different from the estimated effect), and Very low certainty (the true effect is probably markedly different from the estimated effect);** High unexplained heterogeneity;*** Few studies included in the meta-analysis with a small number of outcome observations. Table 3Certainty of the evidence of the outcomes included in the meta-analysis. Adverse effects of oral daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) in men who have sex with men (MSM) and transgender women (TGW).OutcomeParticipants (studies)Relative effect [RR (95%CI)]Anticipated absolute effects [% (95%CI)] Certainty *OutcomeWithout PrEPWith PrEPDifference Any grade 3 or 4 event7,541 (4 RCTs)0.99 (0.83-1.18)10.610.4 (8.8-12.5)0.1% lower (1.8 lower to 1.9 higher)⨁⨁⨁⨁ HighDaily oral PrEP use was not associated with any grade 3 or 4 eventAny serious adverse event8,683 (7 RCTs)1.04 (0.58-1.87)5.96.2 (3.4-11.1)0.2% higher (2.5 lower to 5.2 higher)⨁⨁⨁◯ Moderate **Daily oral PrEP use was not associated with any serious adverse eventChanges in creatinine4,946 (6 RCTs)0.79 (0.40-1.56)1.91.5 (0.8-3.0)0.4% lower (1.2 lower to 1.1 higher)⨁⨁⨁⨁ HighDaily oral PrEP use was not associated with renal dysfunctionGrade 3 or 4 hypophosphatemia3,145 (3 RCTs)0.56 (0.15-2.10)1.20.7 (0.2-2.5)0.5% lower (1.0 lower to 1.3 higher)⨁⨁⨁◯ Moderate ***Daily oral PrEP use was not associated with renal dysfunction95%CI: 95% confidence interval; RCT: randomized clinical trial; RR: risk ratio.Note: the risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI).* GRADE levels of evidence: High certainty (the authors have a lot of confidence that the true effect is similar to the estimated effect), Moderate certainty (the authors believe that the true effect is probably close to the estimated effect, but could also be markedly different), Low certainty (the true effect might be markedly different from the estimated effect), and Very low certainty (the true effect is probably markedly different from the estimated effect);** High unexplained heterogeneity;*** Few studies included in the meta-analysis with a small number of outcome observations. Certainty of the evidence of the outcomes included in the meta-analysis. Adverse effects of oral daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) in men who have sex with men (MSM) and transgender women (TGW). 95%CI: 95% confidence interval; RCT: randomized clinical trial; RR: risk ratio. Note: the risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI). * GRADE levels of evidence: High certainty (the authors have a lot of confidence that the true effect is similar to the estimated effect), Moderate certainty (the authors believe that the true effect is probably close to the estimated effect, but could also be markedly different), Low certainty (the true effect might be markedly different from the estimated effect), and Very low certainty (the true effect is probably markedly different from the estimated effect); ** High unexplained heterogeneity; *** Few studies included in the meta-analysis with a small number of outcome observations. Discussion Main findings of the review In this study, we reviewed clinical trials and cohort studies on the adverse effects of oral PrEP in MSM and TGW. This is the first systematic review to assess the adverse effects of daily oral PrEP in MSM and TGW. The results of this systematic review showed that most studies on PrEP use did not present a risk of serious adverse events. The meta-analysis confirmed these observations, with the lack of statistically significant association with serious adverse outcomes in the control group. Daily oral PrEP in MSM, young MSM, and TGW showed no statistically significant association with the occurrence of serious adverse events, grade 3 or 4 adverse events, serious changes in creatinine levels (grade 3+4), and grade 3 or 4 hypophosphatemia. Thus, this study showed that the daily use of PrEP was safe and well tolerated in the study population. These findings are important, since adverse events can reduce adherence to PrEP. Adherence is a major challenge for effective PrEP implementation, particularly among young MSM and TGW 16 , 42 . Although our meta-analysis focused on clinical trials and cohort studies, the adverse events found in the studies may determine the effectiveness of this therapy in preventing HIV in MSM and TGW. Moreover, our findings may help prescribers assess the risk-benefit of the use of PrEP by MSM and TGW in clinical practice. Most studies assessed baseline renal parameters and the eligibility of participants. However, these studies did not address renal markers 28 . Renal function was assessed predominantly by measuring serum creatinine levels and estimating creatinine clearance using the Cockcroft-Gault equation 43 . Another correlation of renal function assessment analyzed in this study was the serum phosphate level measured in PrEP users in three studies. Only four studies assessed hepatic function, considering liver transaminases (aspartate aminotransferase and alanine aminotransferase) as the main factors. In the segment of PrEP users, studies have no consensus on the evaluation period of the analyzed renal and hepatic markers. However, many of these studies reported consistent associations, showing that daily oral PrEP does not pose a substantial risk of serious adverse events. These results are greatly relevant, especially for TGW, since their hormone therapy is often based on a combination of estradiol and an antiandrogen 44 . The use of these substances along with PrEP could potentiate or lead to serious adverse reactions, which were not observed in this meta-analysis. Comparisons with other studies in the literature The results of this study, particularly the association between the use of TDF/FTC and the risk of adverse events, are in line with other studies. A systematic review and meta-analysis of 13 studies that compared 15,678 randomized participants who used PrEP (TDF/FTC or TDF) with individuals who used a placebo or received no treatment found no significant difference in the risk of grade 3 or 4 clinical adverse events or serious adverse effects between the groups. Moreover, the authors found no significant difference in the risk of specific adverse renal or bone outcomes 3 . A meta-analysis evaluating the effect of PrEP on serum creatinine level using 10 clinical trials that included 17,220 participants randomized to daily oral PrEP (n = 9,913) and placebo (n = 7,307) groups found the opposite result 6 . Participants assigned to the daily PrEP group had a modestly increased risk of grade 1 or higher creatinine events (odds ratio - OR = 1.36; 95%CI: 1.09-1.71). The absolute risk increase was lower (pooled risk increase 0.6%; 95%CI: 0.1-1.2) 6 . However, these studies were not methodologically adequate to provide robust evidence of this relationship, due to the lack of a subgroup analysis similar to that performed in this study, as well as the risk of bias and the certainty of the meta-analysis evidence. A systematic review and meta-analysis of individual data from PrEP users also showed results similar to ours regarding serious adverse effects. A meta-analysis of 11 clinical trials with 13,523 participants showed that the use of PrEP increases the risk of grade 1 or higher renal adverse events and grade 2 or higher renal events. However, the association between grade 2 and higher events was not statistically significant. Events are rare, non-progressive, and disappear when PrEP is discontinued 5 . A subgroup analysis showed that the highest risks were associated with increasing age and baseline creatinine clearance of 60.00-89.99mL/minute. The study highlighted the importance of screening and monitoring renal function in older individuals, individuals with baseline creatinine clearance < 90mL/minute, and individuals with kidney-related comorbidities 5 . A similar result was identified by the U.S. Preventive Services Task Force review for renal adverse events, but most of them were mild and reversible 45 . A recent meta-analysis found that PrEP was safe for MSM, serodiscordant couples, heterosexual individuals, and injecting drug users. However, unrecognized HIV at the time of notification increases the risk of drug-resistant viral mutations 46 . The meta-analysis of placebo-controlled trial showed no significant difference between the groups for any reported adverse events (RR = 1.01; 95%CI: 0.99-1.03; I2 = 42%) and the risk of serious adverse events (RR = 0.91; 95%CI: 0.74-1.13; I2 = 67), but the meta-analysis for renal function was not presented 46 . These findings reinforce the safety of PrEP, especially in this study with MSM and TGW, who suffered from interpersonal violence, discrimination, and health disparities 47 , which can alter the risk of occurrence and monitoring of adverse events. Limitations and strengths This study has some limitations. The studies reviewed showed a high degree of heterogeneity between them. Besides statistical heterogeneity, the studies had different designs and involved different dosages, duration of exposure, follow-up time, time to event, and frequency of assessment of adverse effects, which may influence our results. Some studies did not report the criteria for assessing adverse effects according to the U.S. Division of AIDS 22 , which limited the inclusion of this information in the meta-analysis. These criteria are important, as they consider the evolution of events in the study population. Moreover, most studies were conducted in countries such as the United States, allowing the comparison of results between countries. This review focused on the assessment of biochemical parameters and did not analyze the adverse effects on bone health markers. We did not assess long-term safety because the maximum follow-up period was two years, focusing only on the use of daily oral PrEP to avoid comparing adverse effects with other types of PrEP. Moreover, the searches were performed by a specialist in systematic reviews and underwent slight variations according to the databases in order to retrieve studies on the topic with more sensitivity. Finally, we did not perform a meta-analysis by type of PrEP, given the small number of studies included in this review and the population, since some studies did not stratify the results for the populations analyzed (MSM and TGW). We also did not perform a subgroup analysis, probably due to the low frequency of adverse events associated with daily oral PrEP. Despite the limitations imposed by the analyzed studies, they were conducted following rigorous methods, qualifying the findings presented in this review. It is possible to highlight the strengths of this study as a comprehensive review and an extensive search of the scientific literature on the topic, in accordance with the PRISMA and Cochrane Collaboration guidelines. The strengths of this study include the assessment of the risk of bias and the certainty of the evidence. Moreover, the study was methodologically rigorous and was performed by independent reviewers, including a gray literature database. Another strength of this systematic review and meta-analysis was the focus, except for renal events, on studies with grade 3 or higher events, which are the most dangerous adverse events and may require medical intervention. Finally, this is the first meta-analysis to assess the potential adverse effects of the use of PrEP among MSM and TGW. Implications and recommendations The high and moderate evidence from this review suggests that the use of daily oral PrEP has few adverse effects in MSM and TGW. The total number of adverse events, any grade 3 and 4 adverse effect, and changes in creatinine and phosphate level were similarly distributed between participants using PrEP and the control group. We recommend recording and reporting adverse events in studies that follow the monitoring recommendations 22 and increasing the number of studies on the use of PrEP in low- and middle-income countries, since most studies have focused on high and middle-income countries. Health services and policies on PrEP should expand information on the minimal risk and safety of its use by individuals with clinically healthy renal and hepatic function to reduce barriers to PrEP in individuals at increased risk of HIV infection.